For patients with advanced non-small cell lung cancer (NSCLC), monoclonal antibodies against the programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 have been approved in various treatment settings [3]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.